Background: Integrin a v b 3 is a molecular marker for the estimation of tumor angiogenesis.
Introduction
A ngiogenesis is the process of new blood vessel formation from the preexisting vasculature. It is well accepted as a biomarker for the growth, invasion, and metastasis of numerous solid tumors. [1] [2] [3] Currently, there is a growing demand for novel noninvasive in vivo imaging techniques for response assessment and the pretherapeutic stratification of patients receiving antiangiogenic therapies. It has been suggested that angiogenesis-targeted imaging can provide an early diagnosis and aid in treatment planning and the monitoring of antiangiogenic cancer therapies.
Integrin a v b 3 is a suitable target for both tumor angiogenesis imaging and antiangiogenic therapy because of its high expression on activated endothelial cells and new blood vessels found in tumors and surrounding tissues, while it is absent in most intact normal tissues. 7, 8 Therefore, integrin a v b 3 is considered an indicator of activated angiogenesis; imaging of integrin a v b 3 overexpression is a promising technique for the assessment of angiogenesis. Labeled synthetic ligands with demonstrated specificity for integrin a v b 3 have proven to be successful agents for in vivo imaging of tumor angiogenesis. 4 In particular, agents based on the amino acid sequence ArgGly-Asp (RGD) have been identified as useful for tumor angiogenesis imaging. [9] [10] [11] A significant correlation between the tracer uptake and the level of angiogenesis has been demonstrated in clinical in vivo studies of tumor imaging performed using radiolabeled RGD peptides. 12, 13 IDA-D-[c(RGDfK)] 2 is a newly developed, cyclic synthetic ligand containing the RGD binding site, with a high affinity (IC 50 = 50 nM) for integrin a v b 3 during angiogenesis.
14 Preclinical imaging studies using 99m Tc-IDA-D-[c(RGDfK)] 2 (also known as BIK-505) and single-photon emission computed tomography (SPECT) have demonstrated substantial and specific uptake of the radiotracer at the sites of integrin a v b 3 overexpression in tumors 14 and high-risk atherosclerotic plaques in discrimination with inflammation. 15 Moreover, a recently published human study demonstrated the preliminary clinical efficacy of Tc-IDA-D-[c(RGDfK)] 2 SPECT in the visualization and localization of activated angiogenesis in brain and lung tumors. 16 In the study, angiogenesis imaging using Human internal radiation dosimetry for a newly developed radiotracer is essential for the risk-benefit assessment of clinical application. In this study, the authors evaluated the wholebody distribution and radiation dosimetry of 99m Tc-IDA-D-[c(RGDfK)] 2 in healthy volunteers using serial emission data sets obtained using a dual head gamma camera system.
Materials and Methods

Healthy volunteers
The present study was approved by the Institutional Review Board of the Seoul National University Bundang Hospital (IRB No.: B-1112-069-004). Informed consent was obtained from all of the individual participants. All the procedures performed were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
The participants were recruited through Internet advertisements and a hospital bulletin board. Six healthy participants (male:female = 2:4; mean age -SD = 68.3 -3.2 years [range, 64-73 years]; mean body weight -SD = 56.5 -10.7 kg [range, 47-77 kg]) voluntarily participated in the study.
Participants were age matched with their previous study against brain tumor and lung cancer patients. 16 They had no clinically significant medical or neurologic conditions and presented with no clinically significant abnormalities on physical, neurologic, and laboratory examinations. 2 was purified using semipreparative high-performance liquid chromatography (HPLC; Eclipse XDB-C18 column; 5 mm, 9.4 · 250 mm; Agilent Co., Palo Alto, CA). Their current study followed the same gradient conditions. All radiochemical processes, including 99m Tc incorporation, HPLC purification, and tC 18 Sep-Pak cartridge purification, were conducted within 60 -5 min. A quality control check, including pH, endotoxin testing, analytic HPLC, and residual solvents measurement by gas chromatography, was performed before human use; a radiochemical purity of 95% was mandatory. Molar radioactivity of Philips ADAC Forte dual-head gamma camera (Philips Medical Systems, Andover, MA) was used to acquire transmission and serial emission scan data sets. The photopeak was centered at 140 keV in a 20% width energy window using low-energy high-resolution collimators. Wholebody transmission scan was performed for attenuation correction using a Cobalt-57 flood source just before the injection of Tc-labeled RGD image studies. 16, [18] [19] [20] The scan speed was 20 cm/min for the whole body for both the transmission and emission scans. The duration of each whole-body scan was about 10.7 min.
The posterior image was mirrored, and the anterior-toposterior pixel-by-pixel geometric average of the counts was determined. The calibration factor [(counts/pixel)/(Bq/pixel)] was obtained to convert counts/pixel into Bq/pixel using whole-body counts and injected doses (MBq). The attenuation was corrected using the transmission scan data and geometrically averaged first emission scan data under an assumption that the subject did not move during the transmission and first emission scans. Attenuation correction factors of the organs were obtained from attenuation corrected and nonattenuation corrected first scan data and were applied to all time-activity curves of the regions of interest (ROIs).
Quantitative analysis and radiation dose estimation
ROIs were manually drawn over the whole-body images at each time point, identifying high uptake organs such as the liver, kidneys, urinary bladder, gallbladder, spleen, brain, and large intestine to obtain the time-activity curves. The radioactivity of 99m Tc-IDA-D-[c(RGDfK)] 2 in each organ was expressed as the percentage injected dose (%ID) per organ calculated as the total activity in the organ ROI (Bq)/injected dose (Bq) · 100.
The number of disintegrations per unit activity administered (residence time) was obtained using the ratio of the cumulative activity and injected dose for each subject. The cumulative activity was obtained from the area under the time-activity curve. The area under the curve was calculated as the trapezoid sum of the observed data and the integral of physical decay for the curve tail after the last scan. The remainder of the body, an important input parameter for OLINDA/EXM 1.1 software (Organ Level Internal Dose Assessment Code, Vanderbilt University, Nashville, TN), was also assessed. If excretion of the radiotracer is prevented, the total residence time, which is the summation of the residence times in all of the organs in the body and the remainder of the body, can be calculated using the following simple equation:
where A 0 is the injected dose, k is the decay constant, and T 1/2 is the physical half-life of the radioisotope. In this study, the total residence time was about 8.67 h because the half-life of 99m Tc was 6.01 h. The excretion of the radiotracer was assessed by the total radiation counts inside of the body contour of the geometrically averaged whole-body images. The residence time in the remainder of the body was obtained from the total residence time, summation of residence times in all of the organs, and excretion from the body.
Finally, the calculated residence times in each organ and the remainder of the body were used as input parameters for the OLINDA/EXM 1.1 software. The OLINDA/EXM 1.1 reports individual organ doses for 24 organs, effective dose (ED), and effective dose equivalent (EDE) using residence time data with reference to adult male and female models. The EDE and ED were calculated as the weighted sum of each individual organ dose. The weighting factors for the EDE and ED were defined from International Commission of Radiation Protection (ICRP) publications 26 (1979) and 60 (1990).
Results
No adverse events were observed. Figure 2 shows a geometrically averaged whole-body image 0, 1, 2, 4, 8, and 24 h postinjection. After the intravenous injection, 99m Tc-IDA-D-[c(RGDfK)] 2 was rapidly taken up by various tissues and organs. High accumulations were observed in the heart, liver, kidneys, and urinary bladder at the initial phase and in the large intestine only at a very late phase. The residence times and cumulative activity percentage in each organ are shown in Table 1 ; high residence times were reported in the liver, large intestine, urinary bladder, and kidneys. The radiation dose to each organ and the effective doses (ED and EDE) obtained using OLINDA/EXM software are listed in Table 2 . As expected, high radiation doses were reported in the upper large intestine (19.28 -4.78 lGy/ MBq), urinary bladder wall (19.15 -6.84 lGy/MBq), kidneys (15.67 -0.90 lGy/MBq), liver (9.13 -1.71 lGy/MBq), and gallbladder wall (9.09 -2.03 lGy/MBq). Whole-body mean EDE and ED were 7.11 -0.58 lGy/MBq and 5.08 -0.53 lGy/ MBq, respectively.
Discussion
Recently, angiogenesis imaging targeting integrin a v b 3 has gained widespread attention due to its value in tumor diagnostics and therapy. Studies, including ours, assessing the correlation of angiogenic activity in tumors with overexpression of integrin a v b 3 and tumor metabolism using Radiotracers for angiogenesis imaging have a potentially broad field of application, spanning from cancer to cardiovascular theranostics. Several RGD peptides have been tested in the recent past, demonstrating that the number of RGD moieties, the isotope, and chelator profoundly affect the synthetic process, binding potential, and in vivo biodistribution. 22 Other research groups have tried to synthesize 99m Tclabeled RGD analogs containing various 99m Tc-chelating moieties such as 2-mercaptoacetyl-glycylglycyl (MAG2) and 6-hydrazinonicotinamide (HYNIC). 23, 24 However, these 99m Tc-chelating moieties of the target compound have significant shortcomings, such as a bulky core size, low metabolic stability, and slow clearance from the normal tissue. Therefore, certain RGD analogs have been formulated to include polyethylene glycol (PEG4) or glycine (G3) linkers to increase the integrin a v b 3 binding affinity in a ''bivalent'' manner and to improve radiotracer excretion kinetics from normal organs. 24 IDA-D-[c(RGDfK)] 2 is a newly developed, cyclic synthetic ligand containing the RGD binding site with a high affinity for integrin a v b 3 during angiogenesis.
14 SPECT/computed tomography (SPECT/CT) is a hybrid imaging modality that can longitudinally diagnose the target environment in the same subject across different time points noninvasively. RGD analogs that are labeled with radioisotopes suitable for SPECT detector systems, such as 99m Tc, can be used as radiotracers for angiogenesis imaging with SPECT/CT. A clear advantage of the 99m Tc-labeled SPECT radiotracer is its potential for clinical use as it is readily available and cost-effective compared to PET.
99m Tc-labeled IDA-D-[c(RGDfK)] 2 is a newly developed radiotracer for SPECT (or gamma camera) to visualize angiogenic lesions and is a promising agent for cancer imaging.
Human internal radiation dosimetry for newly developed radiotracers is essential for the risk-benefit assessment of clinical applications, which might influence the choice of the radiotracer. Therefore, in the present study, the authors evaluated the radiation dose exposure in humans who underwent a whole-body favorable whole-body pharmacokinetics in terms of its high renal and hepatic extraction, rapid clearance through the kidneys, gallbladder, and GI tract and low doses in the other organs. The kidney exhibited high accumulation, suggesting the possibility to be the dose-limiting organ when targeting integrin a v b 3 for antiangiogenic therapy. Although the high kidney accumulation is probably caused by the increased arginine residues, the kidney uptake is comparable to other radiolabeled multimeric cyclic RGD peptides and other peptides. [24] [25] [26] Activity in the liver and kidneys is substantially eliminated 8 h postinjection, with the excretion of the radiotracer through the large intestine and urinary bladder, with some residual activity in the large intestine. The ED and/or EDE values for other SPECT and/or gamma camera radiotracers commonly used clinically are listed in Table 3 ; the ED and EDE values for The present study is limited by its small sample size. Because of the limited number of participants, the authors did not calculate the doses for subject-specific organ volumes. Rather, the authors computed the doses according to the OLINDA/EXM 1.1 reference phantoms. This approach is reasonable for low-dose range radiopharmaceutical compounds typically used in diagnostics, in which patient radioprotection is the main concern, because ED is a metric used for assessing stochastic risk in a population. On the contrary, the use of subject-specific organ masses would be crucial if a therapeutic approach was considered. Another limitation is the quantification of the dual-head gamma camera data. The geometric mean method using simultaneously acquired anterior and posterior images, which the authors adopted here, is certainly useful in activity quantification. However, its accuracy is limited to specific clinical situations. The most fundamental drawback of this method is the fact that it assumes constant attenuation of the photon intensity with the source depth; hence, it does not correct for the contribution of scatter to the counts obtained. This assumption is not valid for the relatively wide window settings used in nuclear medicine. It has been shown that the broad beam attenuation coefficient varies from 0.081 cm -1 for a source at 1-cm depth to 0.122 cm -1 for a source at 15-cm depth in tissue equivalent material using a 30% window. In addition, the method does not take into consideration the effects of the source thickness and inhomogeneity of the attenuating medium. The source thickness and inhomogeneity effects in vivo may be as high as 20% each. 31 As mentioned earlier, integrin a v b 3 is a suitable target not only for tumor angiogenesis imaging but also for antiangiogenic therapy. In an aspect of radiotheranostics, the peptide IDA-D-[c(RGDfK)] 2 is possibly transformed into a therapeutic radiopharmaceutical compound when it is labeled with b-emitting radioisotopes such as rhenium-188 ( 188 Re), as previously reported.
14 Hence, target distribution and dosimetry studies of b-emitting radioisotope labeled IDA-D-[c(RGDfK)] 2 must be performed as previously mentioned, to utilize its strength as a radiotheranostic radiopharmaceutical. In specific, pretherapeutic scans with To conclude, the radiation dosimetry results for 99m Tc-IDA-D-[c(RGDfK)] 2 are comparable to the data reported for other 99m Tc-labeled radiotracers, and thus, possible diagnostic use of the new radiotracer does not escalate the radiation risk to the patient. This study demonstrates that 99m Tc-IDA-D-[c(RGDfK)] 2 is an efficacious and safe radiotracer for imaging integrin a v b 3 expression. 
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